2.7.11.4	(2R)-2-chloro-3-phenylpropanoic acid	-	213705	
2.7.11.4	(2S)-2-chloro-3-phenylpropanoic acid	-	213704	
2.7.11.4	(R)-alpha-chloroisocaproate	-	213703	
2.7.11.4	(S)-alpha-chloroisocaproate	-	213702	
2.7.11.4	2-(N-Morpholino)propane sulfonate buffer	-	29353	
2.7.11.4	2-Chloroisohexanoate	no inhibition by (R)(-)-2-chloroisopentanoate; potassium phosphate increases sensitivity to this inhibitor	4199	
2.7.11.4	2-Chloroisohexanoate	no inhibition by (R)(-)-2-chloroisopentanoate; potassium phosphate increases sensitivity to this inhibitor; (R)(+)-isomer is twice as effective as (S)(-)-isomer; site-specific inhibitor	4199	
2.7.11.4	2-Chloroisohexanoate	-	4199	
2.7.11.4	2-Chloroisohexanoate	ATP does not protect; i.e. 2-chloro-4-methylpentanoate, strong	4199	
2.7.11.4	2-Chloroisohexanoate	enhanced by monovalent cations and further enhanced by phosphate	4199	
2.7.11.4	2-Chloroisohexanoate	50% inhibition at 0.014 mM, no inhibition with histone II-S as substrate	4199	
2.7.11.4	2-Chloroisohexanoate	50% inhibition at 0.014 mM	4199	
2.7.11.4	2-oxo-3-methylpentanoate	more effective than 2-oxoisopentanoate	2813	
2.7.11.4	2-oxo-3-methylpentanoate	-	2813	
2.7.11.4	2-oxobutanoate	-	390	
2.7.11.4	2-oxohexanedioate	-	10490	
2.7.11.4	2-Oxohexanoate	-	1100	
2.7.11.4	2-oxoisocaproate	more effective than 2-oxo-3-methylpentanoate and 2-oxoisopentanoate	1174	
2.7.11.4	2-oxoisocaproate	-	1174	
2.7.11.4	2-oxoisocaproate	kinetics, 40% inhibition at 0.065 mM	1174	
2.7.11.4	2-oxoisopentanoate	less effective than 2-oxoisohexanoate and 2-oxo-3-methylpentanoate	1270	
2.7.11.4	2-oxoisopentanoate	-	1270	
2.7.11.4	2-oxopentanoate	-	968	
2.7.11.4	2-oxopentanoate	kinetics	968	
2.7.11.4	3,6-dichlorobenzo[b]thiophene-2-carboxylic acid	-	213698	
2.7.11.4	3-chloro-6-fluorobenzo[b]thiophene-2-carboxylic acid	-	213699	
2.7.11.4	3-methyl-2-oxobutanoate	-	829	
2.7.11.4	4-(2-Thienyl)-2-oxo-3-butenoate	2 mM	43396	
2.7.11.4	4-(3-Thienyl)-2-oxo-3-butenoate	2 mM	15545	
2.7.11.4	4-hydroxyphenylacetate	-	1708	
2.7.11.4	4-hydroxyphenyllactate	weak	10530	
2.7.11.4	4-hydroxyphenylpyruvate	-	423	
2.7.11.4	4-hydroxyphenylpyruvate	very weak: 3-hydroxyphenylpyruvate	423	
2.7.11.4	4-methyl-2-oxopentanoate	-	722	
2.7.11.4	acetate	weak, in vivo and in vitro	47	
2.7.11.4	acetoacetyl-CoA	-	187	
2.7.11.4	acetoacetyl-CoA	40% inhibition at 0.01 mM	187	
2.7.11.4	acyl-CoA	-	492	
2.7.11.4	ADP	-	13	
2.7.11.4	ADP	competitive	13	
2.7.11.4	ADP	kinetics	13	
2.7.11.4	ADP	product inhibition	13	
2.7.11.4	ADP	50% inhibition at 0.4 mM, inhibition can be reversed by 2 mM Mg2+	13	
2.7.11.4	alpha-Chloroisocaproate	inhibits the enzyme by releasing it from the BCKD complex via dissociation	10573	
2.7.11.4	alpha-Chloroisocaproate	-	10573	
2.7.11.4	alpha-Ketoisocaproate	inhibits the enzyme by releasing it from the BCKD complex via dissociation	4785	
2.7.11.4	alpha-ketoisovalerate	inhibits the enzyme by releasing it from the BCKD complex via dissociation	2643	
2.7.11.4	ATP	-	4	
2.7.11.4	ATP	50% inhibition at 0.2 mM, inhibition can be reversed by 2 mM Mg2+	4	
2.7.11.4	branched-chain 2-oxo acids	-	20938	
2.7.11.4	Ca2+	weak	15	
2.7.11.4	Ca2+	-	15	
2.7.11.4	CDP	50% inhibition at 0.4 mM, inhibition can be reversed by 2 mM Mg2+	212	
2.7.11.4	Clofibric acid	-	8069	
2.7.11.4	Clofibric acid	in vivo and in vitro	8069	
2.7.11.4	CoA	-	18	
2.7.11.4	CTP	50% inhibition at 0.25 mM, inhibition can be reversed by 2 mM Mg2+	60	
2.7.11.4	dexamethasone	decreases enzyme expression level in renal tubule cells	1159	
2.7.11.4	Dichloroacetate	weak	1160	
2.7.11.4	Dichloroacetate	-	1160	
2.7.11.4	Dichloroacetate	ATP slightly protects	1160	
2.7.11.4	Dichloroacetate	50% inhibition at 1.8 mM	1160	
2.7.11.4	diphosphate	-	17	
2.7.11.4	Furfurylidenepyruvate	1.85 mM	12533	
2.7.11.4	GDP	50% inhibition at 0.2 mM, inhibition can be reversed by 2 mM Mg2+	53	
2.7.11.4	GTP	50% inhibition at 0.06 mM, inhibition can be reversed by 2 mM Mg2+	37	
2.7.11.4	heparin	-	227	
2.7.11.4	heparin	40% inhibition at 0.012 mg/ml	227	
2.7.11.4	heparin	50% inhibition at 0.002 mM	227	
2.7.11.4	Hydrocinnamic acid	-	12555	
2.7.11.4	isobutyryl-CoA	-	842	
2.7.11.4	isovaleryl-CoA	-	784	
2.7.11.4	malonyl-CoA	-	76	
2.7.11.4	methylhydrocinnamic acid	-	213706	
2.7.11.4	methylmalonyl-CoA	-	790	
2.7.11.4	methylmalonyl-CoA	40% inhibition at 0.2 mM	790	
2.7.11.4	Mg2+	at concentrations above 1.5 mM, activation below	6	
2.7.11.4	MgATP2-	-	108	
2.7.11.4	additional information	no inhibition by 2-chloropropionate	2	
2.7.11.4	additional information	no inhibition by GTP	2	
2.7.11.4	additional information	no inhibition by acetyl-CoA; no inhibition by coenzyme A	2	
2.7.11.4	additional information	no inhibition by lactate	2	
2.7.11.4	additional information	-	2	
2.7.11.4	additional information	no inhibition by acetate; no inhibition by acetyl-CoA; no inhibition by lactate; no inhibition by methylcrotonyl-CoA, beta-hydroxy-beta-methylglutaryl-CoA, crotonyl-CoA, octanoyl-CoA, succinyl-CoA, propionyl-CoA, 0.1 mM each, propionate, beta-hydroxybutyrate, acetoacetate, malonate, alpha-ketomalonate, succinate, citrate, oxaloacetate, FAD+, NADPH, 2 mM; no inhibition by NADH, NAD+ 1 mM each	2	
2.7.11.4	additional information	no inhibition by DL-leucine	2	
2.7.11.4	additional information	binding of thiamin diphosphate cofactor to branched-chain alpha-keto acid decarboxylase/dehydrogenase, which induces a phosphorylation loop conformation change, inhibits the phosphorylation of the protein by the BCKD kinase, no inhibition of phosphorylation of mutant R287A, D295A, Y300F, and R301A E1B components	2	
2.7.11.4	additional information	clofibric acid and thiamine diphosphate do not affect the protein-protein interaction of BDK with the BCKD complex	2	
2.7.11.4	additional information	negligible inhibition by butanoic acid and dodecanoic acid	2	
2.7.11.4	additional information	no inhibition by coenzyme A; no inhibition by isovaleryl-CoA	2	
2.7.11.4	additional information	no inhibition by isovaleryl-CoA	2	
2.7.11.4	N,N'-(1,2,5-oxadiazole-3,4-diyl)bis(3,6-dichlorobenzo[b]thiophene-2-carboxamide	-	213701	
2.7.11.4	N-(4-acetamido-1,2,5-oxadiazol-3-yl)-3,6-dichlorobenzo[b]thiophene-2-carboxamide	-	213700	
2.7.11.4	n-Octanoate	-	6004	
2.7.11.4	n-Octanoate	40% inhibition at 0.5 mM	6004	
2.7.11.4	NADP+	-	10	
2.7.11.4	NADP+	40% inhibition at 1.5 mM	10	
2.7.11.4	octanoic acid	-	1649	
2.7.11.4	phenylacetate	-	776	
2.7.11.4	phenylacetate	strong	776	
2.7.11.4	phenylbutyrate	-	20805	
2.7.11.4	Phenyllactate	-	4045	
2.7.11.4	Phenyllactate	strong	4045	
2.7.11.4	phenylpyruvate	in vivo and in vitro	198	
2.7.11.4	phenylpyruvic acid	-	8175	
2.7.11.4	pyruvate	-	31	
2.7.11.4	pyruvate	weak	31	
2.7.11.4	thiamine	-	642	
2.7.11.4	thiamine diphosphate	inhibits phosphorylation of wild-type E1, mutant E1-S303A and mutant E1-D296A/S303A, but not phosphorylation of mutant E1-H292A	91	
2.7.11.4	thiamine diphosphate	-	91	
2.7.11.4	thiamine diphosphate	Ca2+-dependent inhibition	91	
2.7.11.4	trioctanoin	-	11031	
2.7.11.4	UDP	50% inhibition at 0.25 mM, inhibition can be reversed by 2 mM Mg2+	26	
2.7.11.4	UTP	50% inhibition at 0.1 mM, inhibition can be reversed by 2 mM Mg2+	65